MOTS-c and SS-31: mitochondrial peptides — energy, endurance, and slowing aging

Mitochondria are the power plants of every cell. They produce ATP — the universal “currency” of energy in the body. With age, mitochondria lose efficiency: their DNA gets damaged, the electron transport chain malfunctions, and the production of free radicals increases. This process is called mitochondrial dysfunction, and it underlies most age-related diseases — from diabetes and neurodegeneration to sarcopenia and chronic fatigue.

Two research peptides — MOTS-c and SS-31 — target precisely this problem, but they work through different mechanisms.

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA Type-c) is a 16-amino-acid peptide encoded by mitochondrial DNA. It was discovered in 2015 by the group of Professor Pinchas Cohen at the University of Southern California. This was a revolutionary discovery: it was the first time mitochondria were shown to produce their own signaling peptides that affect the metabolism of the whole body.

The main effects of MOTS-c:

• Activation of the AMPK pathway — the “metabolic switch” that activates the breakdown of fats and glucose. AMPK is the same pathway that is activated by physical exercise and calorie restriction. MOTS-c, in essence, mimics the effect of training at the molecular level.
• Improved insulin sensitivity — cells begin to absorb glucose from the blood more efficiently, and blood sugar levels decrease.
• Stimulation of fat metabolism — beta-oxidation of fatty acids is accelerated, and fat stores are used as fuel.
• Anti-inflammatory action — reduces the level of systemic inflammation associated with obesity and aging.

A study (Lee et al., Cell Metabolism, 2015): mice given MOTS-c showed resistance to weight gain on a high-fat diet, improved glucose tolerance, and increased physical endurance. In older mice, MOTS-c significantly improved metabolic parameters, bringing them closer to those of young animals.

SS-31 (D-Arg-Dmt-Lys-Phe-NH2) is a synthetic tetrapeptide developed by Professor Hazel Szeto at Cornell University. Unlike most antioxidants, which cannot penetrate into the mitochondrion, SS-31 selectively accumulates on the inner mitochondrial membrane thanks to its electrostatic interaction with cardiolipin.

The mechanism of action of SS-31:

• Binding to cardiolipin — a phospholipid that is critically important for the function of the electron transport chain. With age, cardiolipin becomes oxidized, which disrupts ATP production. SS-31 protects it from oxidation.
• Optimization of the electron transport chain — stabilizes the supercomplexes (complexes I, III, IV), increasing the efficiency of energy production and reducing the “leakage” of electrons that generates free radicals.
• Reduction of oxidative stress — it is not a classic antioxidant (it does not “scavenge” radicals) but instead prevents their formation at the source.
• Restoration of mitochondrial dynamics — normalizes the processes of mitochondrial fusion and fission, the disruption of which is a marker of aging.

• MOTS-c is a “metabolic optimizer.” It reprograms cellular metabolism, activates fat burning, and improves endurance. It acts systemically, through AMPK signaling. It is better suited for metabolic goals: weight loss, blood sugar control, and boosting energy during workouts.
• SS-31 is a “mitochondrial protector.” It protects and repairs the mitochondria themselves at the membrane level. It acts locally, at the point of energy production. It is better suited for anti-aging, chronic fatigue, post-COVID recovery, and neuroprotection.

An analogy can be drawn: MOTS-c is the “coach” that makes the body work more efficiently. SS-31 is the “mechanic” that repairs the cells’ power plants. Both are needed, but for different tasks.

MOTS-c:

• Excess weight against a background of metabolic syndrome
• Insulin resistance, elevated blood sugar
• Athletes seeking to increase endurance
• People 40+ with a slowed metabolism
• A combination with retatrutide for enhanced fat burning

SS-31:

• Chronic fatigue that does not resolve after rest
• Post-COVID syndrome with a loss of strength
• Age 50+ — prevention of age-related neurodegeneration
• Heart failure (in the clinical-trial phase)
• Advanced-level anti-aging protocols

MOTS-c is being actively studied in the context of metabolic syndrome, type 2 diabetes, and aging. SS-31 (under the name Elamipretide) has completed several phase 2–3 clinical trials for the treatment of mitochondrial diseases (Barth syndrome) and heart failure. Both peptides represent the cutting edge of biogerontology — the science of the biological mechanisms of aging.